Differences in bio-incompatibility among four biocompatible dialyzer membranes using in maintenance hemodialysis patients

Renal Failure

Volumn 33, Issue 7, 2011, Pages 682-691

  Zhang, Dong Liang ^a   Liu, Jing ^a   Cui, Wen Ying ^a   Ji, Dan Ying ^a   Zhang, Yue ^a   Liu, Wen Hu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Biocompatibility; Dialyzer; Hemodialysis; Membrane flux

Indexed keywords

C REACTIVE PROTEIN; CELLULOSE TRIACETATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; INTERLEUKIN 13; INTERLEUKIN 1BETA; POLY(METHYL METHACRYLATE); POLYETHERSULFONE; POLYSULFONE;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD CELL COUNT; BLOOD LEVEL; COHORT ANALYSIS; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOLUTE;

BIOCOMPATIBLE MATERIALS; FEMALE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 79960785031     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.589943     Document Type: Article

References (22)

1. Bowry SK, Kuchinke-Kiehn U, Ronco C. The cardiovascular burden of the dialysis patient: The impact of dialysis technology. Contrib Nephrol. 2005;149:230-239. (Pubitemid 43265020)
2. Varela MP, Kimmel PL, Phillips TM, et al. Biocompatibility of hemodialysis membranes: Interrelations between plasma complement and cytokine levels. Blood Purif. 2001;19:370-379. (Pubitemid 34701466)
3. MacLeod A, Daly C, Khan I, et al. Comparison of cellulose, modified cellulose and synthetic membranes in the hemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev. 2001;(3):CD003234.
4. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int. 2006;10:162-167.
5. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5):440-451.
6. Boger RH, Zoccali C. ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl. 2003;4:23-28. (Pubitemid 38234491)
7. Kielstein JT, Boger RH, Bode-Boger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA)-In vivo and in vitro evidence of significant protein binding. Clin Nephrol. 2004;62:295-300. (Pubitemid 39386806)
8. Bergström J, Wehle B. No change in corrected beta 2- microglobulin concentration after cuprophane hemodialysis. Lancet. 1987;1:628-629. (Pubitemid 17024248)
9. Krieter DH, Lemke HD, Wanner C. A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal. Artif Organs. 2008;32:547-554. (Pubitemid 352000184)
10. Wingard RL, Husni L, et al. Effect of themembrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int. 1996;49:551-556. (Pubitemid 26050330)
11. Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol. 1990;1:150-161.
12. Martin-Malo A, Castillo D, Castro M, et al. Biocompatibility of dialysis membranes: A comparative study. Nephrol Dial Transplant. 1991;6(Suppl. 2):55-58.
13. Krane V, Krieter DH, Olschewski M, et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis. 2007;49:267-275. (Pubitemid 46178399)
14. Delmez JA, Yan G, Bailey J, et al. Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO Study. Am J Kidney Dis. 2006;47:131-138. (Pubitemid 41828275)
15. Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20(3):645-654.
16. Schiffl H, Lang SM, Stratakis D, et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001;16:1863-1869. (Pubitemid 32821419)
17. Kalousova M, Kielstein JT, Hodkova M, et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif. 2006;24:439-444. (Pubitemid 46030085)
18. GrootemanMP,Wauters IM, Teerlink T, et al. Plasma imethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif. 2007;25:281-289. (Pubitemid 47074644)
19. Aoike I. Clinical significance of protein adsorbable membranes- long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant. 2007;22(Suppl 5):v13-v19.
20. Yamashita AC, Tomisawa N. Importance of membrane materials for blood purification devices in critical care. Transfus Apher Sci. 2009;40:23-31.
21. Yamashita AC, Tomisawa N. Membrane materials for blood purification in critical care. Contrib Nephrol. 2010;166:112-118.
22. Opatrny K Jr, Krouzzecky A, Polanska K, et al. Does an alteration of dialyzer design and geometry affect biocompatibility parameters. Hemodial Int. 2006;10:201-208.